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Abstract
Background: IFN-c and IL-2 cytokine-profiles define three functional T-cell subsets which may correlate with pathogen load
in chronic intracellular infections. We therefore investigated the feasibility of the immunospot platform to rapidly
enumerate T-cell subsets by single-cell IFN-c/IL-2 cytokine-profiling and establish whether immunospot-based T-cell
signatures distinguish different clinical stages of human tuberculosis infection.
Methods: We used fluorophore-labelled anti-IFN-c and anti-IL-2 antibodies with digital overlay of spatially-mapped colour-
filtered images to enumerate dual and single cytokine-secretingM. tuberculosis antigen-specific T-cells in tuberculosis patients
and in latent tuberculosis infection (LTBI). We validated results against established measures of cytokine-secreting T-cells.
Results: Fluorescence-immunospot correlated closely with single-cytokine enzyme-linked-immunospot for IFN-c-secreting
T-cells and IL-2-secreting T-cells and flow-cytometry-based detection of dual IFN-c/IL-2-secreting T-cells. The untreated
tuberculosis signature was dominated by IFN-c-only-secreting T-cells which shifted consistently in longitudinally-followed
patients during treatment to a signature dominated by dual IFN-c/IL-2-secreting T-cells in treated patients. The LTBI
signature differed from active tuberculosis, with higher proportions of IL-2-only and IFN-c/IL-2-secreting T-cells and lower
proportions of IFN-c-only-secreting T-cells.
Conclusions: Fluorescence-immunospot is a quantitative, accurate measure of functional T-cell subsets; identification of
cytokine-signatures of pathogen burden, distinct clinical stages of M. tuberculosis infection and long-term immune
containment suggests application for treatment monitoring and vaccine evaluation.
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Introduction
Although T cell interferon-gamma release-assays (IGRA) are a
major advance in diagnosis of LTBI, reliance on IFN-c as the sole
read-out means they provide only limited biological information
which is clinically interpreted in a binary fashion, indicating either
presence or absence of infection. A major limitation of current T
cell-based diagnosis is the inability to monitor treatment response
or distinguish active from latent TB [1–3].
Simultaneous measurement of IFN-c and IL-2 at the single cell
level identifies T cell cytokine profiles which reflect their memory
phenotype and defines three main functional T cell subsets:
effector cells that mainly secrete IFN-c only, effector-memory cells
primarily secreting both IFN-c and IL-2, and central memory cells
secreting only IL-2 [4]. These T cell subsets correlate with antigen
and pathogen load in vivo, as exemplified by studies of chronic viral
infections and tuberculosis (TB) and quantification of these key T
cell subsets is a promising approach for diagnosis and monitoring
of infectious diseases [5–10], as well as for identifying correlates of
protective immunity [4,11–19] and measuring vaccine immuno-
genicity [20–22].
The existing regulatory-approved commercial IGRAs are
robust, extensively validated platforms for measuring the cell-
mediated immune response to MTB antigens in routine clinical
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practice. However, measurement of IFN-c as the sole marker of
cellular immunity precludes exploiting the additional biological
and clinical insights that could be provided by direct quantification
of functional T cell subsets from patient blood samples. Given that
the immunospot platform quantifies individual antigen-specific
cytokine-secreting T cells, it might have potential for multiple
cytokine profiling at the single cell level but development of dual-
colour ELISpot has been hampered by the ambiguity of
enumerating dual-colour spots due to masking of weaker signal
from one colour-substrate by stronger signal from the second
colour-substrate [23,24]. Replacing enzymatic colorimetric signal
with fluorophores emitting light at different wavelengths which are
read through separate filters could in principle circumvent this
problem. When each fluorophore-labelled monoclonal antibody
detects a different cytokine [25], digital overlay of spatially-
mapped images from the corresponding filters could enable
detection of dual cytokine-secreting T cells based on co-
localisation of different fluorophores [26] thereby generating a
third, combined colour, or ‘footprint’ of dual cytokine-secreting
cells.
We comprehensively examined for the first time the feasibility
and accuracy of the membrane-based immunospot platform for
rapid enumeration of the three key functional T cell subsets based
on single-cell cytokine-profiling for IFN-c and IL-2. We first
validated this approach against established colour-ELISpot and
flow-cytometry-based measures of single and dual cytokine
secretion, respectively. We then hypothesised that fluorescence-
immunospot would be able to distinguish distinct cytokine profiles
in M. tuberculosis (MTB) antigen-specific T cells in different clinical
stages of human TB infection, each cytokine signature being
associated with different levels of pathogen and antigen load.
Methods
Participants
Ethical approval was granted by the NHS National Research
Ethics Service, St Mary’s Research Ethics Committee (London,
UK) reference 07/H0712/85. Consenting adult patients were
prospectively recruited from St Mary’s Hospital, Imperial College
Healthcare NHS Trust, London. Written informed consent was
given in all cases.
The cross-sectional group of untreated active TB comprised 32
patients (table 1) and the cross-sectional group of treated TB
comprised 24 patients sampled 3 or more months after
commencing treatment (table 1). 6 of the patients recruited before
treatment were also sampled after 3 months and included in the
cross-sectional treated TB cohort. The nested longitudinal cohort
comprised 19 of the untreated patients sampled pre-treatment and
again 2-3 months later (6 patients at 3 months and 13 patients at 2
months). The LTBI group comprised 26 untreated persons
diagnosed on the basis of positive IGRA results with one or more
documented risk factors for TB exposure in whom active TB had
been clinically and radiographically excluded [27]; 13 were
recently infected and 13 remotely infected (see table 1 footnotes).
23 healthy BCG-vaccinated laboratory staff were recruited as
healthy controls.
Purification of lymphocytes from peripheral blood
PBMC were isolated from 40 millilitres of heparinised whole
blood less than 4 hours after drawing by Ficoll-PaquePLUS density
centrifugation (GE Healthcare, Amersham, UK) washed twice in
RPMI 1640 (Sigma-Aldrich, Irvine, UK), and cryopreserved in
heat-inactivated foetal calf serum supplemented with 10% DMSO
(Sigma-Aldrich). After no more than 12 months storage in liquid
N2, cells were thawed at 37uC for one minute, washed twice in
RPMI supplemented with 10% foetal calf serum and resuspended
in AIM-V media (Invitrogen, Paisley, UK) for viability checking by
trypan blue exclusion. Sample viability ranged from 80–98% and
cells were used in assays with no rest period.
Ex vivo colour IFN-c ELISpot
Pre-coated plates (Mabtech, Nacka, Sweden) were equilibrated
with AIM-V media for 30 min before seeding. Duplicate wells
were seeded with 2.56105 PBMCs in AIM-V and contained: no
peptide, 5 mg/ml PHA (MP Biomedicals, Illkirch, France), 20 mg/
ml tuberculin PPD (Satens Serum Institute, Copenhagen, Den-
mark) or peptide pools containing 15-mer peptides overlapping by
10 amino acids (10 mg/ml final concentration; Pepceuticals Ltd,
Nottingham, UK) spanning the length of ESAT-6 (17 peptides) or
CFP-10 (18 peptides). Plates were incubated for 18 hours at 37uC
with 5% CO2 then washed 5 times with 200 ml/well PBS and
developed for one hour with 100 ml/well ALP-conjugated IFN-c
detection antibody diluted to manufacturer’s instructions (Mab-
tech) before washing 5 times with PBS and incubating for 7
minutes with 50 ml/well BCIP/NBTPLUS (Moss, Pasadena, MD,
USA) and thoroughly washed with water, as previously described
[(ref28)].
Spot-forming cells (SFCs) were counted using automated
ELISpot reader (Autoimmun Diagnostika GmbH, Strassberg,
Germany) with pre-defined threshold size and intensity settings
(see Table S1).
Ex vivo colour IL-2 ELISpot
The ex-vivo IL-2 ELISpot was performed in the same manner
as the ex-vivo IFN-c-ELISpot with the following differences, Plates
(MultiscreenHTS
TM IP, Millipore, Billerica, MA) were activated
with 15 ul/well 35% ETOH for one minute before washing 5
times with 200 ml/well sterile water and coating overnight at 4uC
with 10 ug/ml coating IL-2 antibody (Mabtech). Plates were
washed 5 times with 200 ml/well sterile PBS before seeding with
cells and antigen as per IFN-c-ELISpot assay. After 18 hours
incubation, plates were washed and developed for 2 hours with
100 ml/well of 2.5 mg/ml biotinylated anti-IL-2 antibody (IL2-II-
biotin, Mabtech) followed by five PBS washes and 100 ml/well of
streptavidin-ALP diluted to manufacturer’s instructions (Mabtech)
for one hour. After 5 PBS washes, plates were incubated for 20
minutes with 50 ml/well BCIP/NBTPLUS and washed thoroughly
with water. SFCs were counted using the same ELISpot reader as
for IFN-c-ELISpot with separate pre-defined threshold size and
intensity settings (see Table S1).
Ex vivo IFN-c/IL-2 fluorescence-immuospot
Plates (MultiscreenHTSTM IPFL, Millipore, Billerica, MA) were
activated with 15 ul/well 35% ETOH for one minute before
washing 5 times with 200 ml/well sterile water and coating
overnight at 4uC with 20 mg/ml anti-IL-2 and 20 mg/ml anti-IFN-
c antibodies (Mabtech). Duplicate wells were seeded with PBMCs
and incubated with test and control conditions exactly as for
colour ELISpot but with the addition of anti-CD28 IgG antibody
(Mabtech, final concentration 0.1 mg/ml). After 18 hours, plates
were washed then incubated with 2 mg/ml monoclonal FITC-
conjugated anti-IFN-c (7-B6-FITC, Mabtech) and 2.5 mg/ml
biotinylated anti-IL-2 detection (IL2-II-biotin, Mabtech) antibod-
ies. After washing, plates were incubated with fluorophore-labelled
secondary antibodies, anti-FITC-PF488P and streptavidin-PF555
(Mabtech) at 1 mg/ml, washed again and incubated at room
temperature for 15 minutes with 100 ml/well fluorescence
enhancer (Mabtech) before being emptied and air-dried.
Functional T-Cell Signatures in TB
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SFCs were counted by automated fluorescence plate reader (iSpot,
Autoimmun Diagnostika GmbH) fitted with colour filters for FITC
and Cy3 which detect PF488P and PF555 fluorophores respectively.
iSpot software version 5 was used to count plates using pre-defined
threshold size and intensity settings for spots (see Table S1 for full
instrument settings). The iSpot software digitally overlays single
stained images to give a third dual-stained image for the enumeration
of dual-cytokine-secreting cells. The rate of false-positive reporting of
dual-spots (due to co-localization of spots from different cells) by the
iSpot automated plate reader is ,2% when single-stained spots per
well are 500 or less, which was the case for 98.5% of responses in our
dataset (Autoimmun Diagnostika, unpulblished data on file).
Positive response threshold settings for immunospot
assays
Antigen-specific responses were calculated by subtracting the
average number of SFCs in duplicate donor-specific negative
control wells from SFCs in test wells for each donor. Thresholds
for a positive response for each cytokine were pre-defined as two
standard deviations above the mean of all negative control wells
(figure 1). This equated to 8 IFN-c SFCs and 12 IL-2 SFCs more
than the negative control wells for each patient for fluorescence-
immunospot and 5 IFN-c SFCs and 8 IL-2 SFCs more than the
negative control wells for colour ELISpot. This threshold was
chosen in order to encompass 95% of variation within negative
controls (figure 1). Positive ESAT-6 and CFP10 responses were
summated for each participant to give ESAT-6/CFP-10 responses.
Cytokine secretion assay
PBMCs from healthy BCG-vaccinated donors were incubated in
the presence of no antigen, PPD (20 mg/ml) or Staphylococcal
Enterotoxin B (SEB, Sigma, 4 ng/ml data not shown) for 4 hours at
37uC (3 million cells per condition). PBMCs were then washed twice
with MACS buffer (PBS, 0.5% BSA and 2 mM EDTA (Sigma-
Aldrich)) and centrifuged for 10 minutes at 4uC. Cell pellets were
resuspended in 80 ml per test condition of cold RH5 (RPMI
supplemented with 5% heat-inactivated human AB serum (Sigma-
Aldrich)). Ten microlitres of IFN-c catch reagent and 10 ml of IL-2
catch reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) were
added per test condition and incubated on ice for 5 minutes. Five
millilitres of warm RH5 was added and cells rotated at 37uC in 5%
CO2 for 45 min; cells were then incubated on ice for 10 min in 9 ml
ice-cold MACS buffer before centrifugation and resuspension in
80 ml cold MACS buffer. After staining with 10 ml allophycocyanin-
conjugated IL-2-specific detection antibody, 10 ml FITC-conjugated
IFN-c-specific detection antibody (Miltenyi Biotec) and 3 ml
Table 1. Demographic and clinical characteristics of study participants.
Partcipant characteristics
Untreated
Active TB{
(n = 32)
Treated
Active TB{
(n = 24)
Latent TB
infection
(n =26)
Median age in years (range) 33 (21–60) 35.5 (19–69) 32 (18–79)
Female gender (%) 15 (46.8) 10 (41.6) 11 (42.3)
Ethnic Origin (%) -Asian 17 (53.1) 12 (50) 3 (11.5)
-Black African 8 (25) 8 (33.3) 11 (42.3)
-Caucasian 6 (18.8) 2 (8.3) 7 (26.9)
-Other 1 (3.1) 2 (8.3) 5 (19.2)
Exposure to active TB case (%) - Recent* n/a n/a 13 (50)
- Remote** n/a n/a 13 (50)
BCG Vaccination status (%) -Vaccinated 25 (78.1) 20 (83.3) 15 (57.7)
-Unvaccinated 5 (15.6) 3 (12.5) 8 (30.8)
-Unknown 2 (6.3) 1 (4.2) 3 (11.5) (0)
Clinical characteristics at time of diagnosis
MTB culture positive where tested (%) 18/30 (60) 11/22 (50) n/a
Histological evidence of granulomas where tested (%) 12/18 (66.7) 10/17 (58.8) n/a
Radiological evidence of TB where tested (%) 26/30 (86.7) 21/23 (91.3) n/a
Site of disease (%) - Lymphatic 15 (46.9) 11 (45.8) n/a
-Pulmonary 11 (34.4) 7 (29.2) n/a
-Pleural 1 (3.1) 2 (8.3) n/a
-Disseminated 4 (12.5) 3 (12.5) n/a
-Extrapulmonary 1 (4.2) 1 (4.2) n/a
TST positive where tested (%) 23/27 (85.2) 18/21 (85.7) 17/21
IGRA positive where tested (%) 15/15 (100) 11/11 (100) 26/26 (100)
Median length of treatment in months (range) 0 (0–0.3) 6 (3–9) 0
{5 patients with 1–4 days treatment and 2 with 1–2 weeks treatment at recruitment.
{11 patients at 3 months, 9 at 4–6 months and 7 at 7–9 months after initiating treatment.
*Recent infection: persons exposed to an infectious TB case less than 6 months before recruitment and resident in the UK for more than 2 years.
**Remote infection: persons who immigrated to the UK from a high-incidence country more than 2 years ago with no known exposure to TB within the last 2 years.
nt = not tested.
doi:10.1371/journal.pone.0015619.t001
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phycoerythrin-conjugated anti-CD3 antibody (BD Biosciences,
Oxford, UK) for 15 min on ice. Cells were washed twice and
resuspended in 100 ml MACS buffer. Dead cells were excluded by
staining with 7-amino-actinomycin-D (BD Biosciences) just before
acquisition by flow-cytometry on an LSR II flow-cytometer (BD
Biosciences) and analysed using FlowJo software (Tree Star, Ashland,
OR). At least 300,000 events were captured per sample. The number
of PPD-specific IL-2/IFN-c secreting cells per million CD3+
lymphocytes was calculated by subtracting the number of dual-
stained unstimulated CD3+ lymphocytes from the number of dual-
stained PPD-stimulated CD3+ lymphocytes. To derive the number of
cytokine secreting T cells per million PBMC, the number of PPD-
specific CD3+ lymphocytes was multiplied by the proportion of
PBMC that were CD3+ for each donor.
Statistical analysis
Spearman’s rank correlation was used to measure correlation
between data from fluorescence-immunospot and pre-existing assays
with 99% confidence intervals. Mann-Whitney 2-tailed U test was
used to identify statistically significant differences between groups.
GraphPad prism version 4 was used for statistical analysis. The range
of absolute frequencies of the antigen-specific functional T cell subsets
across individuals and inter-individual variation were considerable
and frequencies of IFN-c-only, IL-2-only and dual cytokine-secreting
T cells in each donor were therefore analysed as proportions.
Data can be made available to academic investigators on
written request by agreement with Prof A. Lalvani at a.lalvani@
imperial.ac.uk.
Results
Demographic and clinical characteristics of study
participants
Demographic and clinical characteristics of the study partici-
pants are summarized in table 1. Patients were categorised into
three clinical groups: untreated active TB (n= 32), treated active
TB (n = 24) and untreated latent TB infection (n = 26). There were
no significant differences in age, gender, ethnicity or BCG
vaccination status between the groups, except that the latently
infected group contained a lower proportion of Asians. No LTBI
Figure 1. Comparison of number of spot-forming-cells (SFC) found in negative control wells of fluorescence-immunospot and
colour ELISpot. Overlaid histograms of number of spot-forming-cells (SFC) found in negative control wells of colour ELISpot and fluorescence-
immunospot measuring IL-2 (A) and IFN-c (B). Median values for IL-2 SFC and IFN-c SFC were higher in the fluorescence-immunospot compared to
the colour ELISpot (C & D, both P,0.0001). This was attributed to the use of co-stimulatory anti-CD28 antibody in the fluorescence-immunospot to
overcome the effects of sequestering of IL-2 by membrane-bound IL-2 antibodies. The resultant increased background cytokine-secretion in negative
control wells was adjusted for by subtracting negative control responses from antigen-specific responses.
doi:10.1371/journal.pone.0015619.g001
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donors had subclinical active TB as none developed active disease
during 12 months follow-up. Our study population has a very low
(4%) prevalence of HIV-coinfection and no participants had any
clinical or laboratory features suggestive of HIV infection [29].
Enumeration of IFN-c and IL-2 -secreting cells by
fluorescence-immunospot correlates closely with
measurement by colour ELISpot
PBMC from 90 independent blood samples from 76 subjects
with active TB or latent TB infection were incubated with media
alone or stimulated with peptides from the MTB-specific proteins
early secreted antigenic target 6 (ESAT-6), culture filtrate protein-
10 (CFP-10) or purified protein derivative (PPD). Secretion of the
two cytokines was measured in parallel by colour IFN-c-ELISpot,
colour IL-2-ELISpot and fluorescence-immunospot. Numbers of
SFCs in negative control wells in the parallel assays are compared
in figure 1. The fluorescence-immunospot negative control wells
had significantly higher numbers of IL-2 (A and C) and IFN-c
positive spots (B and D) compared to the colour ELISpots. The
mean number of negative control SFC/well was used to calculate
assay-specific thresholds for positive responses (see Methods).
PBMC from 8 BCG-vaccinated healthy controls were also
stimulated with the same panel of antigens in the fluorescence-
immunospot assay and no positive responses to ESAT-6 or CFP-
10 were detected (data not shown).
Numbers of IFN-c and IL-2 SFCs enumerated by the colour
and fluorescent assays were strongly and significantly correlated
(Figure 2, Spearman’s rank r = 0.93 and 0.84 respectively,
p,0.0001 for both cytokines). The slope of the linear relationship
was 1.55 for IFN-c and 1.45 for IL-2; the higher numbers of IFN-c
and IL-2 SFCs detected in the fluorescence-immunospot com-
pared to conventional colour ELISpot are attributable to co-
stimulation of antigen-specific T cells resulting from inclusion of
co-stimulatory anti-CD28 IgG antibody in our protocol (see
Methods) to counterbalance sequestering of IL-2 by membrane-
bound anti-IL-2 capture antibody [30]. The resultant increased
background cytokine-secretion in negative control wells was
adjusted for by subtracting negative control responses from
antigen-specific responses.
For both IFN-c-secreting and IL-2-secreting T cells, responses
to PPD and ESAT-6 and CFP-10 peptide pools were equally
strongly correlated between the colour and fluorescent immuno-
spot assays (Figure 2) indicating that inter-assay correlation is
independent of the antigen used.
Comparing positive and negative responses for all 3 antigens
between the fluorescent and colour assays revealed that 90% of
IFN-c results and 87% of IL-2 results were concordant (Table S2).
Enumeration of dual IFN-c/IL-2 secreting T cells by
fluorescence-immunospot gives equivalent values to
measurement by direct cytokine staining and
flow-cytometry
To confirm that fluorescence-immunospot accurately measures
dual-cytokine secreting cells, we compared the number of PPD-
specific IFN-c/IL-2-secreting cells enumerated by fluorescence-
immunospot with numbers detected by dual staining using the
cytokine secretion assay (CSA) in PBMC from 15 BCG-vaccinated
healthy donors. Figure 3a shows fluorescence-immunospot IL-2,
IFN-c and digitally-overlaid dual images from a representative donor
with CSA results from the same donor shown in figure 3b. The
Figure 2. Comparison of the number of antigen-specific spot-forming cells (SFC) detected by fluorescence-immunospot and colour
ELISpot. PBMC from 90 independent samples from 76 donors were stimulated with PPD (diamonds), ESAT-6 (hollow circles) or CFP-10 (grey filled
circles). IFN-c (A) or IL-2 producing cells (B) were enumerated by colour ELISpot and fluorescence-immunospot. Correlation between results of the 2
tests was tested by Spearman’s rank correlation. Responses to PPD and peptide pools of ESAT-6 and CFP-10 were each strongly correlated between
the colour and fluorescent assays for enumerating IFN-c-secreting cells (r = 0.89 CI: 0.83–0.94, r = 0.89 CI: 0.9–0.95, r = 0.83 CI: 0.72–0.90 for PPD, ESAT-
6 and CFP-10 respectively) and IL-2-secreting cells (r = 0.84 CI: 0.73–0.90, r = 0.73 CI: 0.56–0.84, r = 0.70 CI: 0.53–0.82 for PPD, ESAT-6 and CFP-10
respectively).
doi:10.1371/journal.pone.0015619.g002
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number of dual cytokine-secreting SFC detected by fluorescence-
immunospot across the 15 donors was strongly and significantly
correlated with the number of dual-cytokine secreting cells detected
by CSA (Spearman’s rank, r =0.83, p=0.0001) (figure 3c).
Fluorescence-immunospot identifies distinct T cell
cytokine signatures in untreated and treated TB patients
We used the validated fluorescence-immunospot to quantify and
compare functional T cell subsets in TB patients before and during
treatment. Median frequencies of total cytokine-secreting T cells
specific for ESAT-6/CFP-10 peptides (248 (IQR 96-860) per
million PBMC) and PPD (524 (IQR 196-1152)) in untreated TB
patients were not significantly different from those in treated
patients (268 (IQR 128-748) for ESAT-6/CFP-10 and 728 (IQR
324-1044) for PPD) (p= 0.76, p = 0.35, respectively).
The proportions of ESAT-6/CFP-10 and PPD-specific cytokine-
secreting T cells that were IFN-c-only, dual-IFN-c/IL-2 or IL-2-
only in the cross-sectional cohorts of untreated TB versus treated
patients are shown in figure 4. TB patients on treatment had a
significantly higher proportion of ESAT-6/CFP-10-specific IFN-c/
IL-2 secreting T cells and a significantly lower proportion of ESAT-
6/CFP-10-specific IFN-c-only secreting cells than the untreated
cohort (figure 4a, b & d, p= 0.0005 and p=0.008 respectively) with
no significant difference in the proportion of ESAT-6/CFP-10-
specific IL-2 only-secreting cells (figure 4c). The difference in the
proportions of PPD-specific IFN-c/IL-2-secreting T cells between
untreated and treated patients was not statistically significant
(figure 4f, p = 0.077); however, the proportion of PPD-specific IFN-
c-only-secreting T cells was significantly higher in untreated patients
(figure 4e, p= 0.047) while the proportion of IL-2-only secreting T
cells was significantly lower (figure 4g p= 0.019).
Fluorescence-immunospot reveals consistent changes in
T cell cytokine signatures within individual TB patients
tracked longitudinally during treatment
Nineteen untreated active TB patients were re-tested after 2–3
months treatment (figure 5): median frequencies of total cytokine-
secreting T cells specific for ESAT-6/CFP-10 peptides and
for PPD per million PBMC were 388 (IQR 148-972) and 792
(IQR 124-1276) pre-treatment and 132 (IQR 88-952) and 916
(IQR 324-1120) after 2-3 months treatment, respectively. The
change in total cytokine-secreting T cells specific for ESAT-6/CFP-
10 (p= 0.03), but not for PPD (p= 0.66), was statistically significant.
Figure 3. Comparison of the number of dual IFN-c/IL-2 –secreting cells detected by cytokine secretion assay (CSA) and
fluorescence-immunospot. PBMC from 15 healthy BCG-vaccinated volunteers were stimulated with PPD and IFN-c–secreting, Il-2-secreting and
dual IFN-c/IL-2–secreting cells were enumerated by CSA (gating on CD3+ lymphocytes) and fluorescence-immunospot. Fluorescence-immunospot IL-
2, IFN-c and digitally-overlaid dual images from a representative donor are shown in A with CSA results from the same donor shown with percentage
of cells stated in each quadrant shown in B. Correlation between the numbers of dual IFN-c/IL-2-secreting cells detected by the 2 tests was tested by
Spearman’s rank correlation (C).
doi:10.1371/journal.pone.0015619.g003
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Figure 4. Cytokine responses to ESAT-6/CFP-10 and PPD in patients with Active TB before (n=32) and during treatment (after 3–9
months of treatment, n=24). PBMC from patients with active TB were stimulated with ESAT-6/CFP-10 (A-D) or PPD (E-H) and the number of IFN-c-
only secreting cells (A,E) dual IFN-c/IL-2 –secreting cells (B,F) and IL-2-only secreting cells (C,G) were enumerated by fluorescence-immunospot. Data
are expressed for all responding patients as the percentage of the total number of cytokine-secreting cells detected which were IFN-c-only, IL-2-only
or dual IFN-c/IL-2 –secreting cells. Mean proportions of ESAT-6/CFP-10–specific and PPD-specific cytokine-secreting cells for each patient group are
depicted as pie charts in figures D and H respectively (where white = IFN-c only, Grey = IFN-c/IL-2 and black = IL-2 only-secreting cells).
doi:10.1371/journal.pone.0015619.g004
Figure 5. Cytokine responses to ESAT-6/CFP-10 and PPD in patients with active TB followed longitudinally before and during
treatment (2 or 3 months of treatment). PBMC from 19 patients with active TB were isolated before treatment and after 2 or 3 months treatment
and stimulated with ESAT-6/CFP-10 (A–C) or PPD (D–F) and the number of IFN-c-only secreting cells (A,D) Dual IFN-c/IL-2–secreting cells (B,E) and IL-
2-only secreting cells (C,F) were enumerated by fluorescence-immunospot. Data are expressed for all responding patients as the percentage of the
total number of cytokine-secreting cells detected which were IFN-c-only, IL-2-only or dual IFN-c/IL-2–secreting cells.
doi:10.1371/journal.pone.0015619.g005
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Eighteen of 19 patients displayed a decrease in the proportion of
IFN-c-only secreting ESAT-6/CFP-10-specific T cells after
treatment (figure 5a, p= 0.0003). The proportion of ESAT-6/
CFP-10-specific IFN-c/IL-2-secreting cells increased significantly
after treatment in all but one patient (figure 5b, p= 0.002). There
was no significant change in the proportions of ESAT-6/CFP-10-
specific IL-2-only-secreting cells which remained low (under 30%)
in all but 3 patients (figure 5c). The proportion of PPD-specific
IFN-c-only-secreting cells decreased significantly during treatment
and the proportion of dual IFN-c/IL-2-secreting cells increased
significantly (figure 5d-e, p = 0.0016 and p=0.0008 respectively).
The proportion of PPD-specific IL-2-only-secreting cells increased
non-significantly in the majority of patients during treatment
(figure 5f, p = 0.07). All 19 patients responded successfully to anti-
tuberculous therapy and the consistent immunological changes
observed were associated with consistent improvements in clinical
status (weight gain and resolution of presenting symptoms and
pyrexia where present), microbiologic status (conversion of sputum
cultures to negative in the 12 patients who were initially culture-
positive) and radiological findings on chest radiography and
computerised axial tomography.
Fluorescence-immunospot identifies distinct T cell
cytokine signatures that distinguish LTBI from active TB
Median absolute frequencies of total cytokine-secreting T cells
specific for ESAT-6/CFP-10 peptides and for PPD per million
PBMC were 248 (IQR 96-860) and 524 (IQR 196-1152) in
untreated active TB and 364 (IQR 128-1164) and 724 (IQR 380-
1400) in the group with LTBI, respectively, with no significant
difference between active TB patients and LTBI (p= 0.84,
p = 0.14, respectively).
Having determined that the MTB-specific T cell cytokine
profile distinguishes the low in vivo antigen load state of treated TB
from the high antigen load state pre-treatment, we postulated that
it would also distinguish the low pathogen load state of LTBI from
untreated active TB. Untreated active TB patients had a
significantly higher proportion of ESAT-6/CFP-10 specific IFN-
c only-secreting T cells and a significantly lower proportion of
ESAT-6/CFP-10 specific IFN-c/IL-2-secreting and IL-2 only-
secreting T cells than persons with untreated LTBI (figures 5a, b,
c, d, p= 0.02, p = 0.04 and p= 0.03 respectively). After stratifica-
tion for duration of latent infection, the differences from active TB
in the single cytokine-secreting ESAT-6/CFP-10-specific func-
tional T cell subsets remained significant for the remotely-infected
(p = 0.03, p = 0.07 and p= 0.03 for IFN-c-only-secreting, IFN-c/
IL-2-secreting and IL-2-only-secreting T cells, respectively) but not
the recently-infected subgroup (p = 0.15, p= 0.16, p = 0.18,
respectively). In contrast, functional T cell subsets specific for
PPD were not significantly different between untreated active TB
and LTBI (figure 6e, f, g, h). Functional T cell subsets specific for
PPD or ESAT-6/CFP-10-specific were not significantly different
between the two LTBI subgroups although this comparison was
based on low numbers (n = 12 remote vs. n = 11 recent for ESAT-
6/CFP-10 responders).
Discussion
Our findings establish fluorescence-immunospot as a sensitive,
high-throughput platform to enumerate antigen-specific functional
Figure 6. Cytokine responses to ESAT-6/CFP-10 and PPD in untreated active TB patients and persons with latent TB infection (LTBI).
PBMC from 32 untreated patients with Active TB (ATB, circles) and 26 persons with LTBI (diamonds) were stimulated with ESAT-6/CFP-10 (A–D) or PPD
(E–H) and the number of IFN-c-only secreting cells (A,E) dual IFN-c/IL-2 –secreting cells (B,F) and IL-2-only secreting cells (C,G) were enumerated by
fluorescence-immunospot. LTBI data was also subdivided into persons with recent exposure (black triangles, n = 13) and those with remote exposure
to an infectious TB case (hollow triangles, n = 13). Data are expressed for all responding patients as the percentage of the total number of cytokine-
secreting cells detected which were IFN-c-only, IL-2-only or dual IFN-c/IL-2-secreting cells. P values are stated for comparisons of ATB with all LTBI and
remote LTBI only. There was no statistically significant difference between the proportions of IFN-c-only, IL-2-only or dual IFN-c/IL-2 –secreting ESAT-
6/CFP-10-specific cells in ATB and recent LTBI (p = 0.15, p = 0.16, p = 0.18, respectively). There was no statistically significant difference between the
proportions of any PPD-specific cytokine-secreting cells (data not shown). Mean proportions of ESAT-6/CFP-10–specific and PPD-specific cytokine-
secreting cells for each patient group are depicted as pie charts in figures D and H respectively (where white = IFN-c only, Grey = IFN-c/IL-2 and
black = IL-2 only-secreting cells).
doi:10.1371/journal.pone.0015619.g006
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T cell subsets directly ex vivo and validate this platform in the
clinical setting for the first time. We verified that fluorescence-
immunospot gives equivalent results to its colour-based ELISpot
predecessor for detection of IFN-c and IL-2 secretion by
individual antigen-specific T cells, independently of the antigen
used. Furthermore, absolute frequencies of dual cytokine-secreting
T cells enumerated by fluorescence-immunospot were tightly
correlated with those enumerated by the flow-cytometric-based
method of CSA, confirming that digital co-localisation of red and
green SFCs in fluorescence-immunospot is an accurate measure of
dual cytokine-secreting T cells. Although strongly correlated with
ELISpot, frequencies of antigen-specific T cells enumerated by
fluorescence-immunospot were generally somewhat higher due to
the use of anti-CD28 for costimulation, as is commonly done in
ICS. However, negative control wells also included anti-CD28 and
thresholds for positive results were derived from these wells; the
impact of co-stimulation was thus taken into account by our
methodology and concordance for positive and negative results
between the assays was high.
Following validation, we used fluorescence-immunospot to
identify signatures of functional T cell subsets corresponding to
the differing pathogen and antigen loads in distinct clinical stages
of TB infection. The proportion of ESAT-6/CFP-10-specific IFN-
c-only secreting cells was significantly lower in treated TB patients
compared to untreated patients and decreased in 18 of 19 patients
followed longitudinally during treatment. Conversely, the propor-
tion of ESAT-6/CFP-10-specific IFN-c/IL-2-secreting cells was
significantly higher in treated compared to untreated TB patients
and increased in 18 of 19 patients followed longitudinally.
Studies with IFN-c release assays (IGRAs) have shown that
ESAT-6 and CFP-10-specific IFN-c-secreting T cells often decline
at the population level in TB patients during treatment, but this
trend masks substantial inter-individual variation with some
patients showing no decline and others an increase [3,6,31-34]
making IGRAs unsuitable for monitoring treatment response or
test of cure [3,6,35]. However, dissecting out the composition of
ESAT-6/CFP-10-specific IFN-c-secreting T cell populations in
patients during the substantial reductions in pathogen load
induced by the induction phase of anti-TB treatment revealed
remarkably consistent dynamic changes in the underlying IFN-c-
only-secreting T cells and dual IFN-c/IL-2-secreting T cells that
together comprise the overall IFN-c response, with the former
declining and the latter increasing in 18 out of 19 patients. Given
that all 19 patients responded well to anti-TB treatment these
dynamic MTB-specific T cell functional signatures suggest a
biomarker of treatment response and decreasing mycobacterial
load. Ours is the only study of functional T cell subsets to present
consistent pair-wise data for individual patients over time. The
only other study longitudinally to track MTB-specific functional T
cell subsets in TB patients, by Caccamo et al, used flow-cytometry
and also found a significant increase in dual IFN-c/IL-2-secreting
T cells after treatment for the study population as a whole [36].
Although the shift towards dual IFN-c/IL-2-secreting T cells is
emerging as a promising biomarker of treatment response, large-
scale clinical studies are now required to determine its clinical
utility and should include patients who fail to respond to treatment
such as those with multidrug-resistant TB. Caccamo et al also
measured TNF-a and found a reduction in tri-functional ESAT-
6/CFP-10-specific T cells secreting IFN-c, IL-2 and TNF-a with
treatment and, in contrast to the present study and our earlier
cross-sectional study [6], an increase in IFN-c-only-secreting T
cells.
IL-2–only secretion is indicative of long-lived central-memory T
cells and there was no significant increase in these cells at 2–3
months treatment in contrast to the findings in patients at 6–28
months post-treatment using CSA with enrichment [6], suggesting
that several months may be required for circulating MTB-specific
IL-2-only secreting T cells to increase. In contrast, the proportion
of PPD-specific IL-2 only-secreting T cells increased significantly
in the treated compared to the untreated patients and increased
non-significantly in the longitudinal cohort at 2–3 months,
suggesting that the kinetics of emergence of PPD-specific central-
memory cells during treatment are faster than ESAT-6/CFP-10-
specific T cells. The reasons for this difference are unclear but
might relate to the fact that PPD-specific IL-2-secreting T cells
include cross-reactive memory T cells generated by prior BCG
vaccination.
We hypothesised that, in contrast to active TB, latently infected
individuals would display an immunological signature consistent
with persistent low antigen load and long-term immune control,
i.e. one dominated by dual IFN-c/IL-2 secreting effector-memory
T cells accompanied by IL-2-secreting central memory T cells.
Compared to active TB patients, the LTBI donors had a
significantly lower proportion of ESAT-6/CFP-10-specific IFN-
c-only secreting T cells and significantly higher proportions of
ESAT-6/CFP-10-specific dual IFN-c/IL-2-secreting and IL-2-
only secreting T cells, confirming our hypothesis. Consistent with
our results, two recent studies comparing MTB-specific functional
T cell subsets in active TB and LTBI using ICS and flow-
cytometry for IFN-c, IL-2 and TNF-a similarly found that ESAT-
6/CFP-10-specific IL-2-only secreting T cells were significantly
increased in latently infected household contacts in The Gambia
[37] and ESAT-6/CFP-10-specific dual IFN-c/IL-2-secreting T
cells were increased in latently infected healthcare workers in Italy
[36]. Thus, MTB-specific T cells secreting IL-2 (with or without
IFN-c) are preferentially associated with LTBI compared to active
TB, consistent with a role in long-term immune control. This
interpretation is also supported by studies in LTBI with HIV co-
infection, where advancing immunosuppression (and risk of active
TB) are associated with declining MTB-specific IL-2 and dual
IFN-c/IL-2-secreting T cells [38,39] while immune reconstitution
is accompanied by increasing MTB-specific IL-2-secreting central-
memory and dual IFN-c/IL-2-secreting T cells but decreasing
proportions of IFN-c-only secreting T cells [9,40,41]. Notably,
however, MTB-specific T cells simultaneously secreting IFN-c, IL-
2 and TNF-a are higher in active TB than LTBI which argues
against a role for tri-functional cells as mediators of long-term
immune control in humans [36].
Stratification of our LTBI cohort into subgroups that were
recently or remotely infected with MTB suggested that the
differences in T cell cytokine signatures between active and latent
TB were driven by the remotely-infected group who have more of
a central-memory T cell functional signature than persons recently
infected with MTB. Ours is the first analysis of functional T cell
subsets in epidemiologically distinct phenotypes of latent infection
and now requires corroboration in a larger study population to
ascertain whether significant differences in cytokine signature exist
between recent and remote infections. Of note, enumeration of
ESAT-6/CFP-10-specific IFN-c-producing T cells by convention-
al IFN-c ELISpot did not detect immunological differences
between active TB, recent LTBI and remote LTBI other than
an overall increase in IFN-c-producing T cells in active TB [42].
The robustness and simplicity of the fluorescence-immunospot
makes it a promising tool for treatment and vaccine trials in
resource-poor settings. Although advanced flow-cytometry is
increasingly available in laboratory research field stations in the
developing world, the ELISpot platform is generally more widely
available in these settings being less expensive and requiring much
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less equipment. We believe that save for the cost of upgrading to
fluorescence-filters, fluorescence-immunospot is as suitable to
infectious disease and immunological investigations in field sites
in resource-poor settings as ELISpot.
This study establishes fluorescence-immunospot as a valid
method for direct ex-vivo quantification of the three main
functional subsets of antigen specific T cells. Application to
human tuberculosis revealed key immunological differences
between distinct clinical stages of MTB infection. The differences
between active and latent infection, as well as the novel finding
that remote LTBI may be more immunologically distinct from
active TB than recent LTBI, delineate functional T cell subsets
associated with long-term immune control and protective
immunity. T cell functional signatures could potentially serve as
biomarkers of risk of progression which, if validated in prospective
studies with clinical outcomes [43,44], could refine targeting of
preventive therapy in LTBI. The consistent dynamic changes
during treatment, combined with the sensitivity, simplicity and
scalability of the robust immunospot platform as exemplified by
ELISpot IGRA [45], identify this technique as a promising new
tool to monitor TB treatment response in the clinic, evaluate new
therapies for TB in clinical trials and assess immunogenicity of
new T cell-inducing vaccines in the field [8,46,47].
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